In the BioHarmony Drug Report Database
Moexipril
Univasc (moexipril) is a small molecule pharmaceutical. Moexipril was first approved as Univasc on 1995-04-19. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Trade Name
|
Univasc |
|---|---|
Common Name
|
moexipril |
ChEMBL ID
|
CHEMBL1165 |
Indication
|
diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction |
Drug Class
|
Antihypertensives (ACE inhibitors) |
Image (chem structure or protein)